News
TECH
353.18
+1.89%
6.54
Bio-Techne's (NASDAQ:TECH) five-year earnings growth trails the 25% YoY shareholder returns
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders might be concerned after seeing the share price drop 22% in the...
Simply Wall St. · 2d ago
Bio-Techne to acquire single-cell sorting platform provider Namocell
Bio-Techne (NASDAQ:TECH) is acquiring Mountain View, Calif.-based Namocell. Financial terms of the deal were not disclosed in the company's June 22 press release. Namocell provides single cell sorting and dispensing platforms
Seekingalpha · 06/22 12:19
BRIEF-Bio-Techne To Acquire Namocell
reuters.com · 06/22 11:13
Bio-Techne To Acquire Namocell; Terms Not Disclosed
Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to
Benzinga · 06/22 11:04
Bio-Techne to Acquire Namocell for Undisclosed Terms
MT Newswires · 06/22 07:24
Baron Funds: “Bio-Techne (TECH) Can Still Generate Strong Revenue Growth”
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutiona...
Insider Monkey · 06/15 12:26
May U.S. healthcare govt grants, clinical trials & NIH outlays increase vs April, says Baird
U.S. outlays from the National Institutes of Health (NIH), clinical trials, and healthcare government grants for May increased over April and Y/Y, according to Baird Equity Research.  In May, NIH outlays increased ~13%
Seekingalpha · 06/14 14:29
Insider Sell: Bio-techne
MT Newswires · 06/09 17:14
Is it a Wise Decision to Keep Your Bio-Techne (TECH) Position?
Aristotle Capital Management, an independent/employee-owned investment management organization, published its “Aristotle Core Equity” first quarter 2022 investor letter – a copy of which can be downloaded here. For the first quarter of 2022, Aristotle Atla...
Insider Monkey · 05/31 15:41
Bio-Techne Announced Milerson 40,000 Unique RNAscope in situ Hybridization Probes, Targeting Any Gene, Any Tissue, Any Species
Bio-Techne Corporation (NASDAQ: TECH) today announced Advanced Cell Diagnostics (ACD), a brand of Bio-Techne, reached an extraordinary milestone of developing over 40,000 unique RNAscope in situ Hybridization (ISH) probes in over 400 species.
Benzinga · 05/26 11:15
What Is Bio-Techne Corporation's (NASDAQ:TECH) Share Price Doing?
Today we're going to take a look at the well-established Bio-Techne Corporation ( NASDAQ:TECH ). The company's stock...
Simply Wall St. · 05/25 18:33
GLOBAL STUDY DEMONSTRATES ICE3 AND MAURICE CAPILLARY ISOELECTRIC FOCUSING COMPARABILITY IN THE JOURNAL OF ELECTROPHERESIS
Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a global study in the Journal of Electrophoresis: Global Intercompany Assessment of icIEF Platform Comparability for the Characterization of Therapeutic Proteins. This publication rep...
PR Newswire · 05/25 11:00
BIO-TECHNE TO PRESENT AT THE JEFFERIES HEALTHCARE CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022, at 9:30 a.m. EDT. A live webcast of the presentation can b...
PR Newswire · 05/19 11:00
BRIEF-Bio-Techne And Nonagen Bioscience Announce Exclusive Supply Agreement For Nonagen's Oncuria Bladder Cancer Test
reuters.com · 05/12 11:13
Bio-Techne Reports Exclusive Supply Deal With Nonagen Bioscience For Nonagen's Oncuria Bladder Cancer Test, No Terms Disclosed
Techne Corporation (NASDAQ:TECH) and Nonagen Bioscience  today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer
Benzinga · 05/12 11:02
Bio-Techne and Nonagen Bioscience Announce Exclusive Supply Agreement for Nonagen's Oncuria® Bladder Cancer Test
Bio-Techne Corporation (NASDAQ: TECH) and Nonagen Bioscience today announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria® bladder cancer diagnostic panel using xMAP Luminex® technology.
PR Newswire · 05/12 11:00
Bio-Techne Unit, Nonagen Bioscience Sign Manufacturing Deal for Oncuria Bladder Cancer Test
MT Newswires · 05/12 08:27
Insider Buy: Bio-Techne
MT Newswires · 05/11 17:39
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Simply Wall St. · 05/10 17:37
BIO-TECHNE TO PRESENT AT ANNUAL AMERICAN UROLOGICAL ASSOCIATION CONFERENCE IN NEW ORLEANS
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, will have a major scientific presence at the annual American Urological Association Conference (AUA) taking place May 13-16 in New Orleans, LA. Exosome Diagn...
PR Newswire · 05/10 11:00
More
Webull provides a variety of real-time TECH stock news. You can receive the latest news about Bio-Techne Corp through multiple platforms. This information may help you make smarter investment decisions.
About TECH
Bio-Techne Corporation is a developer, manufacturer, and seller of life science reagents, instruments and services for the research, diagnostics, and bioprocessing markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient options for automated western blot and multiplexed ELISA workflow. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits.